Vasodilating mechanisms of levosimendan: involvement of K+ channels

Clicks: 224
ID: 269234
2007
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Star

Ranked #284 of 499 articles by views in Journal of pharmacological sciences

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 499 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Levosimendan, a novel agent developed for the treatment of acute and decompensated heart failure, exerts potent positive inotropic action and peripheral vasodilatory effects. The mechanism of vasodilation by levosimendan may involve reduction of Ca2+ sensitivity of contractile proteins in vascular s …
Reference Key
o2007journalvasodilating Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Yildiz O;;
Journal Journal of pharmacological sciences
Year 2007
DOI
DOI not found
URL
https://www.ncbi.nlm.nih.gov/pubmed/17452812
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE review animals humans pubmed abstract nih national institutes of health national library of medicine simendan hydrazones / pharmacology* pyridazines / pharmacology* pmid:17452812 doi:10.1254/jphs.cp0060010 oguzhan yildiz blood vessels / drug effects blood vessels / physiology potassium channels / physiology* vasodilation / drug effects* vasodilation / physiology vasodilator agents / pharmacology ca2+ desensitization

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.